Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Antibacterial specialist Achaogen is reorganizing to focus on commercializing its antibiotic plazomicin in the U.S. The company will pare back R&D to two programs—a beta-lactam/beta-lactamase inhibitor combination and new aminoglycoside antibiotics. Eighty jobs, or 28% of the firm’s staff, will be eliminated. A raft of top managers will exit Achaogen as well. Meanwhile, immuno-oncology specialist NewLink Genetics will cut 25 jobs from its payroll, a workforce reduction of 30%, and focus research on projects in clinical development.
This article has been sent to the following recipient: